290 related articles for article (PubMed ID: 20847128)
1. Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice.
Morris CA; Selsby JT; Morris LD; Pendrak K; Sweeney HL
J Appl Physiol (1985); 2010 Nov; 109(5):1492-9. PubMed ID: 20847128
[TBL] [Abstract][Full Text] [Related]
2. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
3. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
Xu DQ; Zhao L; Li SJ; Huang XF; Li CJ; Sun LX; Li XH; Zhang LY; Jiang ZZ
Acta Pharmacol Sin; 2021 Jul; 42(7):1080-1089. PubMed ID: 32939036
[TBL] [Abstract][Full Text] [Related]
4. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
[TBL] [Abstract][Full Text] [Related]
5. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
[TBL] [Abstract][Full Text] [Related]
6. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
8. Treatment with rGDF11 does not improve the dystrophic muscle pathology of mdx mice.
Rinaldi F; Zhang Y; Mondragon-Gonzalez R; Harvey J; Perlingeiro RCR
Skelet Muscle; 2016; 6():21. PubMed ID: 27303621
[TBL] [Abstract][Full Text] [Related]
9. SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.
Sarathy A; Wuebbles RD; Fontelonga TM; Tarchione AR; Mathews Griner LA; Heredia DJ; Nunes AM; Duan S; Brewer PD; Van Ry T; Hennig GW; Gould TW; Dulcey AE; Wang A; Xu X; Chen CZ; Hu X; Zheng W; Southall N; Ferrer M; Marugan J; Burkin DJ
Mol Ther; 2017 Jun; 25(6):1395-1407. PubMed ID: 28391962
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
[TBL] [Abstract][Full Text] [Related]
11. Bowman-Birk inhibitor concentrate prevents atrophy, weakness, and oxidative stress in soleus muscle of hindlimb-unloaded mice.
Arbogast S; Smith J; Matuszczak Y; Hardin BJ; Moylan JS; Smith JD; Ware J; Kennedy AR; Reid MB
J Appl Physiol (1985); 2007 Mar; 102(3):956-64. PubMed ID: 17110517
[TBL] [Abstract][Full Text] [Related]
12. The slow-release adiponectin analog ALY688-SR modifies early-stage disease development in the D2.
Bellissimo CA; Gandhi S; Castellani LN; Murugathasan M; Delfinis LJ; Thuhan A; Garibotti MC; Seo Y; Rebalka IA; Hsu HH; Sweeney G; Hawke TJ; Abdul-Sater AA; Perry CGR
Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1011-C1026. PubMed ID: 38145301
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.
Kumar A; Bhatnagar S; Kumar A
Am J Pathol; 2010 Jul; 177(1):248-60. PubMed ID: 20472898
[TBL] [Abstract][Full Text] [Related]
14. Pannexin 1 dysregulation in Duchenne muscular dystrophy and its exacerbation of dystrophic features in mdx mice.
Freeman E; Langlois S; Leyba MF; Ammar T; Léger Z; McMillan HJ; Renaud JM; Jasmin BJ; Cowan KN
Skelet Muscle; 2024 Apr; 14(1):8. PubMed ID: 38671506
[TBL] [Abstract][Full Text] [Related]
15. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
16. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling.
Acuña MJ; Pessina P; Olguin H; Cabrera D; Vio CP; Bader M; Muñoz-Canoves P; Santos RA; Cabello-Verrugio C; Brandan E
Hum Mol Genet; 2014 Mar; 23(5):1237-49. PubMed ID: 24163134
[TBL] [Abstract][Full Text] [Related]
17. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
18. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.
Cofre C; Acuña MJ; Contreras O; Morales MG; Riquelme C; Cabello-Verrugio C; Brandan E
Biofactors; 2015; 41(2):111-20. PubMed ID: 25809912
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy.
Li H; Mittal A; Makonchuk DY; Bhatnagar S; Kumar A
Hum Mol Genet; 2009 Jul; 18(14):2584-98. PubMed ID: 19401296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
